



AGING

From Fundamental Biology to Societal Impact

Edited by Paulo J. Oliveira and João O. Malva



Contents

<i>List of contributors</i>	xxi
<i>Foreword</i>	xxxv
<i>Preface</i>	xxxvii

Section 1 The societal burden of aging

1. Global aging and health determinants in a changing world	3
Miguel Padeiro, Paula Santana and Marcus Grant	
1.1 Introduction	3
1.2 The geographies of a global trend	3
1.2.1 Global patterns and projections	3
1.2.2 Multiscale intraregional variations of the aging process	8
1.3 Environmental health in later life	10
1.3.1 From successful aging to the role of place and inequities	10
1.3.2 How environment affects physical health in old age	11
1.3.3 The subjective experience of place: place attachment and residential normalcy	15
1.4 Global stressors in a changing world	17
1.4.1 Welfare state and neoliberalism	17
1.4.2 Climate change and health in old age	18
1.4.3 Migrations and health in old age	19
1.4.4 Discrimination as a health issue for older persons	21
1.5 Conclusion	21
Acknowledgments	22
References	22
2. Flagship initiatives for healthy living and active aging in Europe: the European Innovation Partnership on Active and Healthy Ageing and the Reference Sites	31
João O. Malva, Daan Bultje, Vicente Traver-Salcedo, Ana Maria Carriazo, Maddalena Illario, Vincenzo De Luca, Lucyna A. Wozniak, Jean Bousquet, Nick Guldemond, Inês Costa, Helena Canhão, Elísio Costa and John Farrel	
2.1 Demographic changes and aging	31
2.2 The European Innovation Partnership on Active and Healthy Ageing	32
2.2.1 European Innovation Partnership on Active and Healthy Ageing cross-cutting initiatives	34
2.3 Reference sites—case studies	34

2.3.1	Ageing@Coimbra Reference Site	34
2.3.2	The Healthy Ageing Network Northern Netherlands	36
2.3.3	Valencia region Reference Site	37
2.3.4	Andalusia Reference Site	38
2.3.5	The Lodz4Generations Reference Site	39
2.3.6	Campania Reference Site (ProMIS network)	41
2.3.7	MACVIA-France Reference Site	42
2.4	Reference Site Collaborative Network	42
2.5	Transition from Horizon 2020 to Horizon Europe—the role of IN-4-Active and Healthy Ageing	44
2.6	Future perspectives	45
	Acknowledgment	46
	References	47
3.	Aging in Africa, challenges and opportunities—the particular case of Cabo Verde	49
	Fernando J. Regateiro, António Correia e Silva, António M.D. Brehm, Dario D. Reis, Deisa S.R.C. Semedo, Edith Pereira, Hélder Spínola, Jorge N. Barreto, Judite M. Nascimento, Maria L. Lima Mendonça and Maria Natalina L. Silva	
3.1	Aging in Africa and West African Region	49
3.2	Geography and climate of Cabo Verde	50
3.3	Cabo Verde, the historical healthy islands	51
3.4	Epidemiology of slave society	51
3.5	Cabo Verde Famines	52
3.6	Cabo Verdean population genetics	53
3.7	Age pyramid of Cabo Verdean population	55
3.8	Urbanization of Cabo Verdean population	55
3.9	Aging and the emergence of a new demographic model	57
3.10	Elderly in Cabo Verde	58
3.11	Health and national health service—philosophy, structures, and budget	59
3.12	Healthy and active aging policies	60
3.13	Aging and poverty	60
3.14	Aging and gender	61
3.15	To a healthy living and active aging in Cabo Verde—the future	62
	References	63
4.	Flagship initiatives to prevent and treat diabetes as a burden of western societies	67
	Peter Goulden and Eugenia Carvalho	
4.1	Introduction	67
4.1.1	Demographics of diabetes and prediabetes	68

4.1.2	Healthcare literacy and numeracy	68
4.1.3	Food insecurity and dietary quality	69
4.1.4	Community engagement	69
4.2	Impact of research: prediabetes	70
4.2.1	The diabetes prevention program study	70
4.2.2	The finnish diabetes prevention study	71
4.3	Lifestyle interventions	71
4.3.1	The national diabetes prevention program	71
4.3.2	Exercise	72
4.3.3	Pharmacologic therapy in prediabetes	72
4.4	Impact of research: diabetes	73
4.4.1	Diabetes self-management education	73
4.5	Summary and conclusions	74
	References	75
5.	Determining factors on active aging in Asia and Oceania: a systematic review	77
	Yuezhong Liu, Rakhi Verma and Yin-Leng Theng	
5.1	Introduction	77
5.2	Methodology	78
5.2.1	Population aging in Asia and Oceania	78
5.2.2	Data sources and search strategies	78
5.2.3	Study selection	79
5.2.4	Bias assessment	79
5.2.5	Data extraction	80
5.3	Results	81
5.3.1	Exergaming/active video games	81
5.3.2	Health wearables and activity trackers	85
5.3.3	Smartphones	85
5.3.4	Web-based programs	96
5.4	Discussion and concluding remarks	105
	References	106
6.	Healthy living and active aging in Latin America and the Caribbean countries: biological, demographic, and epidemiological challenges	113
	João M. Coelho-Filho, Reinaldo B. Oriá, Karla C. Giacomini, Gerly A.C. Brito, Marcos Santos, Veronica Aran, Manoela Heringer, Deiziane V.S. Costa, Ronaldo P. Dias and Vivaldo M. Neto	
6.1	Introduction	113
6.2	Demographic and epidemiological changes in the Latin America and the Caribbean countries	115

6.3	Age-related biological changes and diseases in the context of Latin America and the Caribbean countries	119
6.3.1	Immunosenescence and infectious diseases	121
6.3.2	Age-related intestinal microbiota changes: the role in neurodegenerative and metabolic diseases	126
6.3.3	Common age-related diseases: cancer, vascular diseases, diabetes and neurodegenerative disorders	128
6.4	Health and social initiatives for the promotion of healthy living and active aging	133
6.4.1	Age-friendly initiatives	133
6.4.2	Labor force participation and active aging	135
6.5	Selected health issues among older people: evidence from long-term cohorts in Latin America	137
6.6	Conclusion	150
	References	150

Section 2 The biology of aging

7. Identification of metrics of molecular and cellular resilience in humans and animal models 161

Felipe Sierra

7.1	Biomedicine is focused on disease, not health	161
7.2	Comorbidities are the prevailing characteristic of older age	162
7.3	Chronological versus physiological age	163
7.4	Linking aging to disease: geroscience principles	164
7.5	A common thread: improvement of resilience	166
7.6	Defining resilience at the molecular level	167
7.7	Measuring molecular resilience	169
7.8	We need to develop resilience metrics in animal models	171
7.9	Translation of resilience measurements to humans	172
7.10	Conclusions	172
	References	173

8. A metabolic and mitochondrial angle on aging 175

Ana I. Duarte, Izabela Sadowska-Bartosz, Agnieszka Karkucinska-Wieckowska, Magdalena Lebiezinska-Arciszewska, Carlos M. Palmeira, Anabela P. Rolo, Yaschar Kabiri, Barbara Zavan, Paolo Pinton, Fernanda Borges, Hans Zischka, John G. Jones, Grzegorz Bartosz, Paulo J. Oliveira and Mariusz R. Wieckowski

	Abbreviations	175
8.1	Aging and longevity: revisiting the evolutionary perspectives and controversies	177
8.2	Aging and longevity: challenging the traditional views for mitochondrial-derived oxidative stress	178

8.3	Changes of mitochondrial function and structure associated with aging	181
8.3.1	Oxidative phosphorylation and aging	181
8.3.2	Mitochondrial morphology and dynamics in aging	184
8.4	A metabolic angle on aging	185
8.4.1	Carbohydrate metabolism and aging	185
8.4.2	Lipid metabolism and aging	186
8.4.3	Protein metabolism and aging	187
8.4.4	Nutrient metabolism and caloric restriction	188
8.5	Oxidative stress and aging	188
8.5.1	Reactive oxygen species and their reactions	188
8.5.2	Reactive oxygen species as the cause of aging	192
8.5.3	Antioxidant defense in aging	193
8.5.4	Mitochondrial free radical theory of aging	196
8.5.5	Accumulation of reactive oxygen species-induced damage with aging	199
8.5.6	Age-related oxidative modifications of mitochondria	202
8.6	Potential strategies against aging to increase longevity	208
8.6.1	Metabolic control-related approaches	208
8.6.2	Mitochondria-related antioxidant approaches	216
8.7	Conclusions	225
	Acknowledgments	225
	References	225

9. Intercellular communication and aging 257

Teresa M. Ribeiro-Rodrigues, George Kelly, Viktor I. Korolchuk and Henrique Girao

9.1	Importance of intercellular communication	257
9.2	The defining features of senescence	258
9.3	The mechanisms responsible for the induction of cellular senescence	259
9.4	Senescence associated secretory phenotype	260
9.5	Intercellular communication mediated by gap junctions and connexin channels	261
9.6	Intercellular communication mediated by tunneling nanotubes	264
9.7	Intercellular communication mediated by extracellular vesicles	265
9.8	Concluding remarks	269
	Acknowledgments	269
	References	269

10. Genomic instability and aging 275

Zhiqian Li, Sharath Anugula and Lene Juel Rasmussen

10.1	Introduction	275
10.2	DNA strand breakage-induced genomic instability	277
10.3	Replication-induced genomic instability	277

10.3.1	Replication stress	277
10.3.2	Translesion DNA synthesis	278
10.3.3	Mismatch repair	279
10.4	Transcription-induced genomic instability	279
10.4.1	Transcription-coupled repair	280
10.4.2	Transcription-replication conflicts	280
10.5	Nucleotide pools	280
10.6	Mitochondrial functions in genomic integrity	281
10.6.1	Mitochondrial oxidative stress	281
10.6.2	FOXO in oxidative DNA damage response	282
10.6.3	Mitochondrial genome maintenance	282
10.6.4	Mitochondrial dysfunction	283
10.6.5	Mitophagy	283
10.7	Genomic instability in health and disease	284
10.7.1	Longevity	284
10.7.2	Progeroid syndromes	285
10.7.3	Cancer	286
10.7.4	Neurodegeneration	286
10.8	Aging interventions activating DNA repair	286
10.8.1	Exercise	286
10.8.2	Dietary restriction	287
10.8.3	Nicotinamide adenine dinucleotide	287
10.9	Conclusion and future perspectives	288
	Acknowledgments	288
	References	288
11.	Telomeres and cell homeostasis in aging	297
	Stella Victorelli and João F. Passos	
11.1	What is cellular senescence	297
11.2	Link between cell senescence and telomeres	297
11.3	Critically short telomeres activate a DNA damage response and senescence	298
11.4	Telomere dysfunction can occur in a length-independent manner	299
11.5	Mechanisms by which stress accelerates telomere dysfunction	301
11.6	Telomere-associated DNA damage response foci accumulate during aging and disease	303
	References	306
12.	Cellular senescence during aging	311
	Thomas von Zglinicki	
12.1	Cell senescence is a complex stress response	311
12.2	The building blocks of the senescent phenotype	314

12.2.1	Telomeres and the DNA damage response	314
12.2.2	Senescence-associated secretory phenotype	316
12.2.3	Senescence-associated mitochondrial dysfunction	317
12.2.4	Nutrient signaling	318
12.2.5	Autophagy/mitophagy	318
12.2.6	Epigenetic reprogramming	320
12.3	Senescence during aging in vivo	320
12.3.1	Senescence in postmitotic cells	321
12.3.2	Senescent cell bystander effects	321
12.4	Senolytics and senostatics as anti-aging interventions	322
12.4.1	Senolytics	322
12.4.2	Senostatics	325
12.5	Conclusion	326
	References	326

13. The epigenetics of aging 333

Athanasios Metaxakis, Ilias Gkikas and Nektarios Tavernarakis

13.1	Introduction	333
13.2	Epigenetic alterations and aging	334
13.2.1	Histone depletion	334
13.2.2	Non-canonical histone variants	335
13.2.3	Histone acetylation	335
13.2.4	Histone methylation	336
13.2.5	ATP-dependent chromatin remodeling	337
13.2.6	DNA methylation	338
13.2.7	Non-coding RNA molecules	340
13.3	Epigenetic alterations and age-related diseases	341
13.3.1	Cancer and epigenetics	341
13.3.2	Neuronal diseases and epigenetics	343
13.3.3	Cardiovascular disease and epigenetics	344
13.4	Conclusions	345
	Acknowledgment	347
	Conflict of interest	347
	References	347

14. Disrupted cellular quality control mechanisms in aging 359

Cristina Carvalho, Joana F. Pires, Paula I. Moreira and Nuno Raimundo

14.1	Aging: is it a programmed fate and/or an error accumulation?	359
14.2	Autophagy: an evolutionarily conserved process	360
14.3	Role of autophagy in aging: what can go wrong?	364

14.4	The chase for "eternal youth": can autophagy-directed interventions be the much-desired youth elixir?	366
14.5	Going down the rabbit hole: how lysosomes modulate longevity pathways	370
14.6	Partners in crime: mitochondria and lysosomes need each other	373
	References	374
15.	Stem cells, fitness, and aging	385
	Kristina Kitaeva, Andrey Kiyasov, Albert Rizvanov, Catrin Rutland and Valeriya Solovyeva	
15.1	Introduction	385
15.2	Cell fitness and cell competition	386
15.3	Senescent mesenchymal stem cell phenotype	387
15.4	The functionality changes in senescent mesenchymal stem cells	389
15.5	The role of factors associated with aging	390
15.5.1	Oxidative stress	390
15.6	Genetic and epigenetic aspects	391
15.7	Senescence-associated secretory phenotype and the microenvironment	393
15.8	Therapeutic strategies to rejuvenate and increase fitness	395
15.9	Conclusion	397
	Acknowledgments	398
	References	398
16.	Programming of early aging	407
	Susana P. Pereira, Luís F. Grilo, Renata S. Tavares, Rodrigo M. Gomes, João Ramalho-Santos, Susan E. Ozanne and Paulo Matafome	
16.1	Epidemiology of early life environment and adult aging—developmental origins of health, disease, and aging?	407
16.2	Early life nutrition and programming of adult aging and lifespan	408
16.2.1	Prenatal malnutrition, longevity, and aging	408
16.2.2	Can lactation and early life nutrition contribute to early aging?	410
16.3	Mechanisms underlying early programming of aging	411
16.3.1	Metabolic programming	411
16.3.2	Early cellular miscommunication and cellular senescence	412
16.3.3	Programming of genomic aging and epigenetic alterations	413
16.4	Early programming of aging-related diseases	414
16.4.1	Inflammaging	414
16.4.2	Cognitive decline and dementia	415
16.4.3	Aging-related neoplasia	416
16.4.4	Cardiovascular aging	417
16.4.5	Physical frailty	418

16.5	Transgenerational passage of the aging clock—reproductive cell plasticity and selection	419
16.6	Life interventions to “Re-set the Clock”	421
16.6.1	Nutrigenomics as a strategy to revert early life programming	421
16.6.2	Running against aging—exercise as anti-aging “medicine”	422
16.7	Conclusion	423
	References	424

Section 3 Aging-related physiology, disease and prevention of aging-related diseases

17. Polypharmacy and medication adherence 435

Marta Lavrador, Ana Cristina Cabral, Margarida Castel-Branco,
Isabel Vitoria Figueiredo and Fernando Fernandez-Llimos

17.1	Adherence to therapy and medication management	435
17.1.1	Definition and classification	435
17.1.2	Assessment methodologies	437
17.1.3	Interventions in medication nonadherence	439
17.2	Concept of polypharmacy	442
17.2.1	Potentially inappropriate medication in the elderly	443
17.2.2	Pharmacokinetic and pharmacodynamic changes in older people	444
17.3	Inappropriate polypharmacy management	446
17.3.1	Implicit tools	447
17.3.2	Explicit tools	447
17.4	Epilogue	451
	References	452

18. How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders 455

Edoardo R. de Natale, Heather Wilson, Chi Udeh-Momoh, Jamie K. Ford,
Marios Politis and Lefkos T. Middleton

18.1	Introduction	455
18.2	Molecular imaging of neuroinflammation	457
18.3	Molecular imaging of mitochondria dysfunction and oxidative stress	461
18.4	Molecular imaging of misfolded proteins	462
18.4.1	Molecular tracers of amyloid and tau in vivo PET imaging	463
18.5	In vivo imaging of brain metabolic processes and activity	466
18.5.1	Molecular imaging of cerebral hypometabolism	466
18.5.2	Molecular imaging of brain functional connectivity	467

18.6	Imaging of iron accumulation	469
18.7	Emerging mechanisms of neurodegeneration	471
18.7.1	Glymphatic system	471
18.7.2	O-GlcNAc	472
18.8	Translational use of molecular imaging in neurodegenerative diseases	472
18.9	Conclusions	473
	References	474

19. Physical frailty 493

Yiming Pan and Lina Ma

	Abbreviations	493
19.1	The concept of frailty	495
19.1.1	Frailty as a biological syndrome	495
19.1.2	Frailty as cumulative deficits	495
19.2	Frailty assessment	496
19.2.1	Frailty measurement tools	496
19.2.2	A two-step frailty measurement	496
19.3	The biology of frailty	496
19.3.1	Chronic inflammation	497
19.3.2	Hypothalamic-pituitary axis stress response dysfunction	499
19.3.3	Endocrine dysregulation (dysfunctional hormone regulation)	500
19.3.4	Metabolic imbalance	500
19.3.5	Oxidative stress and mitochondrial dysfunction	501
19.3.6	Genomic factors	502
19.3.7	Metabolomic markers	503
19.4	Animal models of frailty	504
19.5	Interventions to attenuate frailty	506
19.5.1	Pharmacological interventions	506
19.5.2	Nonpharmacological interventions	508
19.6	Conclusion	509
	References	509

20. The extracellular matrix in cardiovascular aging 523

Deolinda Santinha, Andreia Vilaça, Alessandro Ori and Lino Ferreira

	Abbreviations	523
20.1	Introduction	523
20.2	Physiological alterations of the aged heart	525
20.2.1	Aging induces functional and morphologic cardiac alterations	525
20.3	Young cardiac extracellular matrix	526

20.3.1	Collagens	527
20.3.2	Elastin	528
20.3.3	Matricellular proteins: secreted protein, acidic and rich in cysteine and thrombospondin	529
20.3.4	Glycosaminoglycans and proteoglycans	530
20.3.5	Adhesive proteins: fibronectin and laminin	530
20.3.6	Basement membrane	531
20.4	Aged cardiac extracellular matrix	531
20.4.1	Collagen matrix—synthesis, deposition and modification with age	531
20.4.2	Alterations on glycosaminoglycans and proteoglycans in the aged heart	536
20.4.3	Alterations on matrix adhesive proteins with aging	536
20.5	How does the aged heart respond to disease?	536
20.5.1	Age-associated extracellular matrix remodeling in MI	537
20.5.2	Age-associated cardiac extracellular matrix remodeling in heart failure	537
20.6	Conclusions and perspectives	538
	Acknowledgments	539
	References	539

21. Aging-related neoplasia

547

Ana Bela Sarmiento Ribeiro, Maria Filomena Botelho, Ana Cristina Gonçalves, Joana Barbosa Melo, Mafalda Laranjo, Raquel Alves, Joana Jorge, Ilda Patrícia Ribeiro, Salomé Pires, Margarida Abrantes, Vera Constâncio, Carmen Jerónimo, Isabel Marques Carreira, Manuel Santos Rosa and Rafael Solana

21.1	Introduction	547
21.2	Aging and the risk of cancer	548
21.3	Cellular senescence and carcinogenesis	549
21.4	Oxidative stress and carcinogenesis in aging	550
21.5	The hallmarks of aging and neoplasia	551
21.5.1	Cell signaling	551
21.5.2	Telomeres and telomerase	553
21.5.3	Genomic instability	554
21.5.4	Epigenetic aging and neoplasia	556
21.5.5	Proteostasis	557
21.5.6	Metabolism deregulation	558
21.5.7	Immune system dysfunction	559
21.5.8	Persistent viral infection	560
21.5.9	Stem cells	561
21.6	Neoplasias and aging	562
21.6.1	Aging-related neoplasias	562
21.6.2	Cancer therapeutics and aging	564
21.7	Conclusion	567
	References	570

22. Multidimensional frailty as an outcome of biological aging: immunosenescence and inflammaging in the life course perspective	577
M. Cristina Polidori, Luigi Ferrucci and Claudio Franceschi	
22.1 Introduction	577
22.2 Relevance of mechanisms of aging for medicine in the 21st century	578
22.3 Two facets of immunosenescence and inflammaging	579
22.4 Pathophysiological relevance of immunosenescence and inflammaging in the context of frailty: relevance for COVID-19	581
22.5 Concluding remarks and research outlook	583
References	583
Further reading	585

23. Geroscience: a unifying view on aging as a risk factor	587
Cristina Mas-Bargues, Aurora Román-Domínguez, Consuelo Borrás and José Viña	
23.1 Centenarians: a growing population	587
23.2 Morbidity compression in centenarians	587
23.3 Limits of human longevity	589
23.4 Exceptional aging "must-haves"	590
23.4.1 Low-grade inflammation	590
23.4.2 Genetic signature	591
23.4.3 Fine-tuned apoptosis	592
23.4.4 Stem cell pluripotency	593
23.4.5 Healthy lifestyle	593
23.5 Exceptional homeostasis in exceptional aging	595
23.6 Centenarians beyond 120?	596
References	596

Section 4 The future and innovation in aging

24. Aging support with socially assistive robots	603
Jorge Dias and João Sequeira	
24.1 Introduction	603
24.1.1 Social robotics tools for demanding societies	605
24.1.2 Where are we in social robotics?	605
24.2 Where is social robotics heading?	608
24.2.1 Social robots for aging societies	609
24.2.2 User behaviors under uncertainty—the bayesian user model	611
24.2.3 Online knowledge integration using learning	613

24.3	Results with a team of robots	614
24.4	User's attributes from distributed, asynchronous data	616
24.5	Collectively cluster users into distinguishable profiles	618
24.6	Discussion	618
	Acknowledgments	621
	References	621
25.	Machine learning in the context of better healthcare in aging	625
	Jorge Henriques, Caio Ribeiro, Teresa Rocha, Simão Paredes, Paulo de Carvalho, Ana I. Duarte, Alex A. Freitas, Teresa Cunha-Oliveira and Francisco B. Pereira	
25.1	Introduction	625
25.2	Machine learning overview	626
25.3	A review of machine learning applications for aging research	628
25.4	Telemonitoring data mining for hearth failure management	629
25.4.1	Heart failure condition	630
25.4.2	Algorithms for heart failure management	631
25.4.3	Experimental results	634
25.4.4	Discussion	636
25.5	Machine learning for the English Longitudinal Study of Ageing	636
25.5.1	A brief overview of random forest classifiers	637
25.5.2	Preparing the English Longitudinal Study of Ageing-nurse data for the classification task	637
25.5.3	Computational results	639
25.6	Feature importance analysis	640
25.7	Conclusion	643
	References	643
26.	The future of integrated care in aged individuals	649
	Alexandre Lourenço, Maja Furlan de Brito and Bárbara Gomes	
26.1	Introduction	649
26.2	The current model is more and more inadequate	650
26.3	The avoidable suffering	651
26.4	An integrated care approach	651
26.4.1	Healthy aging and disease prevention	652
26.4.2	Patient-centeredness and multimorbidity	653
26.4.3	Dementia	655
26.4.4	Palliative, end life, and bereavement care	656
26.5	Key messages	658
	References	658

27. Moving from reactive to preventive medicine	663
Lina Badimon, Teresa Padro and Gemma Vilahur	
27.1 Introduction	663
27.2 Aging and major chronic diseases	664
27.3 The mechanistic interplay between aging and age-related diseases. In the search of evidence for preventive medicine	664
27.3.1 Immunosenescence and age-related chronic diseases	666
27.3.2 Epigenetic drift and age-related chronic diseases	667
27.4 Age-related diseases—prevention initiatives are in order	667
27.5 Do we have preventive strategies for ameliorating age-related diseases?	668
27.5.1 Non-pharmacological approaches	668
27.5.2 Pharmacological interventions	669
27.6 Cardiovascular disease: the success of prevention	670
27.6.1 Hypertension: the most prevalent cardiovascular risk factor	670
27.7 Low-density lipoproteins-cholesterol lowering: the lower, the better	672
27.7.1 The need to control the obesity pandemic	674
27.7.2 Primordial prevention: the sooner, the better	674
27.8 Concluding remarks	676
References	676
 28. Personalized medicine: will it work for decreasing age-related morbidities?	 683
Christopher R. Martens, Devin Wahl and Thomas J. LaRocca	
28.1 Introduction	683
28.2 Historical perspective	683
28.3 Slowing aging with GeroScience	684
28.3.1 The biological hallmarks of aging	684
28.3.2 A case for personalized aging	686
28.4 Personalized medicine for optimal longevity	686
28.5 Emerging predictors of “biological aging”	687
28.5.1 Epigenetic clocks	687
28.5.2 Transcriptomics	688
28.5.3 Metabolomics and proteomics	688
28.5.4 The gut microbiome	689
28.6 Applying personalized medicine to GeroScience	690
28.6.1 Personalized nutrition	691
28.7 Challenges and barriers to implementing personalized aging	692
28.7.1 Minimizing the risk-benefit ratio	693
28.7.2 Increasing diversity in clinical research	693
28.7.3 Improving adherence and accessibility	694
28.7.4 Innovation in clinical trial design	694

28.7.5 Ethical and policy concerns	696
28.7.6 Cross-disciplinary innovation	696
28.8 Conclusion	696
References	697

29. Interventions that target fundamental aging mechanisms: myths and realities 701

Erin O. Wissler Gerdes, Yi Zhu, Tamar Tchkonja and James L. Kirkland

29.1 Introduction	701
29.2 Pillars of aging	701
29.3 Genomic instability	702
29.3.1 Telomere attrition	702
29.3.2 Epigenetic alterations	702
29.3.3 Loss of proteostasis	703
29.3.4 Deregulated nutrient sensing	703
29.3.5 Mitochondrial dysfunction	703
29.3.6 Cellular senescence	704
29.3.7 Stem cell exhaustion	705
29.3.8 Altered intercellular communication	705
29.4 Unitary theory of fundamental aging processes	705
29.5 Health span versus lifespan	705
29.6 Myths and realities	707
29.6.1 Senolytics	707
29.6.2 Other pharmacological interventions	712
29.6.3 Behavioral/dietary interventions	714
29.7 Clinical trials and treating disease	715
29.7.1 Safety; risk/benefit ratio	715
29.7.2 Combining or sequencing therapies	715
29.7.3 Translational geroscience network	716
29.8 Conclusion	717
Conflict of interest disclosure	717
References	718

30. Being a frail older person at a time of the COVID-19 pandemic 725

Yaohua Chen, Susanne Röhr, Berenice Maria Werle and Roman Romero-Ortuno

30.1 Introduction	725
30.1.1 A minority of community-dwelling older adults are frail	725
30.1.2 Frailty in the time of a pandemic: the "measured" versus the "lived"	726
30.2 The community perspective	727
30.2.1 COVID-19-related challenges in community-dwelling frail older people	728

30.2.2	A glimpse of hope	730
30.3	The hospital perspective	731
30.3.1	Atypical presentations	732
30.3.2	Biological heterogeneity of the population of hospitalized older people	732
30.3.3	Ethical considerations	733
30.3.4	Optimization of the hospital environment and opportunities for in-hospital rehabilitation	734
30.3.5	Hospital-associated deconditioning and post-COVID-19 fatigue	735
30.4	The nursing home perspective	735
30.5	Research on COVID-19 treatments and service development perspectives	737
30.6	Conclusions	739
	Competing interest	739
	Funding	739
	References	740

31. Aging: an illustrated adventure 745

João Ramalho-Santos and André Caetano

Index	755
-------	-----